An external validation of the QCovid risk prediction algorithm for risk of mortality from COVID-19 in adults:a national validation cohort study in England by Nafilyan, Vahé et al.
 
 
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An external validation of the QCovid risk prediction algorithm for
risk of mortality from COVID-19 in adults
Citation for published version:
Nafilyan, V, Humberstone, B, Mehta, N, Diamond, I, Coupland, C, Lorenzi, L, Pawelek, P, Schofield, R,
Morgan, J, Brown, P, Lyons, R, Sheikh, A & Hippisley-Cox, J 2021, 'An external validation of the QCovid
risk prediction algorithm for risk of mortality from COVID-19 in adults: a national validation cohort study in
England', The Lancet Digital Health. https://doi.org/10.1016/S2589-7500(21)00080-7
Digital Object Identifier (DOI):
10.1016/S2589-7500(21)00080-7
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
The Lancet Digital Health
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 17. Aug. 2021
www.thelancet.com/digital-health   Published online May 25, 2021   https://doi.org/10.1016/S2589-7500(21)00080-7 1
Articles
An external validation of the QCovid risk prediction 
algorithm for risk of mortality from COVID-19 in adults: 
a national validation cohort study in England 
Vahé Nafilyan, Ben Humberstone, Nisha Mehta, Ian Diamond, Carol Coupland, Luke Lorenzi, Piotr Pawelek, Ryan Schofield, Jasper Morgan, 
Paul Brown, Ronan Lyons, Aziz Sheikh, Julia Hippisley-Cox
Summary
Background Public policy measures and clinical risk assessments relevant to COVID-19 need to be aided by risk prediction 
models that are rigorously developed and validated. We aimed to externally validate a risk prediction algorithm 
(QCovid) to estimate mortality outcomes from COVID-19 in adults in England.
Methods We did a population-based cohort study using the UK Office for National Statistics Public Health Linked 
Data Asset, a cohort of individuals aged 19–100 years, based on the 2011 census and linked to Hospital Episode 
Statistics, the General Practice Extraction Service data for pandemic planning and research, and radiotherapy and 
systemic chemotherapy records. The primary outcome was time to COVID-19 death, defined as confirmed or 
suspected COVID-19 death as per death certification. Two periods were used: (1) Jan 24 to April 30, 2020, and (2) May 1 
to July 28, 2020. We assessed the performance of the QCovid algorithms using measures of discrimination and 
calibration. Using predicted 90-day risk of COVID-19 death, we calculated r² values, Brier scores, and measures of 
discrimination and calibration with corresponding 95% CIs over the two time periods.
Findings We included 34 897 648 adults aged 19–100 years resident in England. 26 985 (0·08%) COVID-19 deaths 
occurred during the first period and 13 177 (0·04%) during the second. The algorithms had good discrimination and 
calibration in both periods. In the first period, they explained 77·1% (95% CI 76·9–77·4) of the variation in time to 
death in men and 76·3% (76·0–76·6) in women. The D statistic was 3·761 (3·732–3·789) for men and 3·671 
(3·640–3·702) for women and Harrell’s C was 0·935 (0·933–0·937) for men and 0·945 (0·943–0·947) for women. 
Similar results were obtained for the second time period. In the top 5% of patients with the highest predicted risks of 
death, the sensitivity for identifying deaths in the first period was 65·94% for men and 71·67% for women.
Interpretation The QCovid population-based risk algorithm performed well, showing high levels of discrimination for 
COVID-19 deaths in men and women for both time periods. QCovid has the potential to be dynamically updated as 
the pandemic evolves and, therefore, has potential use in guiding national policy.
Funding UK National Institute for Health Research.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction 
The first cases of SARS-CoV-2 infection were reported in 
the UK on Jan 24, 2020, with the first COVID-19 death on 
Feb 28, 2020. As of May 11, 2021, over 127 000 deaths 
from COVID-19 have occurred in the UK, and over 
3 million deaths globally. Emerging evidence throughout 
the course of the COVID-19 pandemic, initially from case 
series and then from cohorts of individuals with 
confirmed SARS-CoV-2 infection, has shown associations 
of age, sex, certain comorbidities, ethnicity, and obesity 
with adverse COVID-19 outcomes such as hospitalisation 
and death.1–8 A growing knowledge base now exists 
regarding risk factors for severe COVID-19. As many 
countries are re-introducing lockdown measures and 
vaccination programmes have started being rolled out, 
the opportunity exists to develop more nuanced guidance9 
that is based on predictive algorithms to inform 
risk-management decisions. Improved knowledge of 
individuals’ risks could also help guide decisions on 
managing occupational risk and in the targeting of 
vaccines to those most at risk. Although several 
risk-prediction models have been developed, a systematic 
review10 found that most models have high risk of bias 
and that their reported performance is optimistic.
The use of primary care datasets such as QResearch, 
with linkage to registries such as death records and 
hospital admissions data, represents an innovative 
approach to clinical risk prediction modelling for 
COVID-19, which has successfully been developed, 
validated, and implemented in the UK National Health 
Service (NHS) over the past 10 years.11–13 The method 
provides accurately coded, individual-level data for many 
people representative of the national population. This 
approach was used to develop the QCovid prediction 
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models,14 drawing on the rich phenotyping of indi-
viduals with demographic, medical, and pharmacological 
predictors to allow robust statistical modelling and 
assessment. Such linked datasets have a track record 
for the development and assessment of established 
clinical risk models including for cardiovascular disease,11 
diabetes (either type 1 or type 2),13 and mortality.12 
Although QCovid predicts both COVID-19-related 
hospital admission and death, the aim of this analysis 
was to validate the outcome that estimates the risks of 
becoming infected and subsequent death due to 
COVID-19 in a large national cohort.
Methods 
Study design and data sources 
The Chief Medical Officer for England asked the New 
and Emerging Respiratory Virus Threats Advisory Group 
to develop and validate a clinical risk prediction model 
for COVID-19 in line with the emerging evidence. The 
resulting QCovid model was developed and validated 
using the QResearch database and reported in accordance 
with Transparent Reporting of a multivariable prediction 
model for Individual Prognosis Or Diagnosis and The 
REporting of studies Conducted using Observational 
Routinely-collected health Data guidelines and with 
input from a patient advisory group. This paper reports 
the validation of the model on an independent data 
source.
We undertook a validation cohort study of individuals 
aged 19–100 years using the UK Office for National 
Statistics (ONS) Public Health Linked Data Asset. This 
dataset is based on the 2011 census in England, linked at 
an individual level using the NHS number to mortality 
records, Hospital Episode Statistics, and the General 
Practice Extraction Service (GPES) data for pandemic 
planning and research. To obtain NHS numbers, the 
2011 census was linked to the 2011–13 NHS patient 
registers using deterministic and probabilistic matching, 
with an overall linkage rate of 94·6%. We excluded 
patients (approximately 13·1%) who did not have a valid 
NHS number or were not found in primary care records. 
To validate the QCovid algorithm, we further linked 
radiotherapy and systemic chemotherapy records on the 
basis of NHS number. The ONS Public Health Linked 
Data Asset includes data on most patients used to 
develop the QCovid algorithm but also includes patients 
registered with practices using information technology 
systems other than Egton Medical Information Systems 
(also known as EMIS), such as The Phoenix Partnership 
(also known as TPP; used by 35% of general practitioner 
[GP] practices in England).
We identified a cohort of all individuals aged 
19–100 years who were enumerated at the 2011 census 
and registered alive and resident in England on 
Jan 24, 2020. Patients entered the cohort on Jan 24, 2020 
(date of first confirmed COVID-19 case in UK) and were 
followed up until they had the outcome of interest or 
July 28, 2020, which is the date up to which linked data 
were available at the time of the analysis. This date also 
extends the period of observation beyond the original 
QCovid study. We divided the study period into two time 
periods: Jan 24, to April 30, 2020, and May 1, to 
July 28, 2020.
Outcomes 
The primary outcome was death involving COVID-19 
(either in hospital or out of hospital), defined as confirmed 
or suspected COVID-19 death as identified by two codes 
of the tenth revision of the International Classification of 
Diseases (U07.1 or U07.2) recorded on the death 
certification. The time-at-risk was calculated from the 
beginning of each period (Jan 24, 2020, or May 1, 2020).
Research in context
Evidence before this study
We searched PubMed for articles about the validation of 
existing predictive models, using  the search terms “COVID-19”, 
“risk”, “prediction”, and “validation”, focusing on studies 
published between March 1 and Dec 31, 2020. No study had 
validated the QCovid risk prediction algorithm. Public policy 
measures and clinical risk assessments relevant to COVID-19 
need to be aided by rigorously developed and validated risk 
prediction models. A recent living systematic review of 
published risk prediction models for COVID-19 found that most 
models were subject to a high risk of bias with optimistic 
reported performance, raising concern that these models might 
be unreliable when applied in practice. A population-based risk 
prediction model, QCovid risk prediction algorithm, has been 
developed to identify adults at high risk of serious COVID-19 
outcomes, which overcomes many of the limitations of 
previous tools.
Added value of this study
Commissioned by the Chief Medical Officer for England, 
we validated the novel clinical risk prediction model QCovid to 
identify risks of short-term severe outcomes due to COVID-19. 
We used national linked datasets from general practice, death 
registry data, and Hospital Episode Statistics data for a 
population-representative sample of more than 34 million 
adults. The risk models had excellent discrimination in men 
and women and were well calibrated. QCovid represents a new, 
evidence-based opportunity for population risk stratification.
Implications of all the available evidence
QCovid has the potential to support public health policy, from 
enabling shared decision making between clinicians and 
patients in relation to health and work risks, to targeted 
recruitment for clinical trials and prioritisation of vaccination, 
for example.
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Predictor variables 
We derived pre-existing conditions and demographic 
characteristics using the same definitions as those 
used to develop the QCovid algorithm. Demographic 
characteristics were taken from the 2011 census. 
Panel: Predictor variables used to validate the QCovid model
• Age in years (continuous)
• Townsend deprivation score (continuous)
• Accommodation (neither homeless nor care home vs care 
home or nursing home)
• Ethnicity in ten categories (Bangladeshi, Black African, 
Black Caribbean, Chinese, Indian, Mixed, Pakistani, White 
British, White other, Other)
• Body-mass index (kg/m²)
• Chronic kidney disease* (no chronic kidney disease, 
stage 3, stage 4, or stage 5)
• Learning disability (no learning disability, Down 
Syndrome, or other learning disability)
• Chemotherapy in the past 12 months (chemotherapy 
group A, B, or C, based on the risk of grade 3 or 4 febrile 
neutropenia [Common Terminology Criteria for Adverse 
Events version 4] or lymphopenia)
• Respiratory cancer
• Radiotherapy in the past 6 months
• Solid organ transplant
• Prescribed immunosuppressant medication by general 
practitioner
• Prescribed leukotriene or long-acting β2 agonists
• Prescribed regular prednisolone
• Diabetes†
• Chronic obstructive pulmonary disease
• Asthma
• Rare pulmonary diseases
• Pulmonary hypertension or pulmonary fibrosis
• Coronary heart disease
• Stroke
• Atrial fibrillation
• Congestive cardiac failure
• Venous thromboembolism
• Peripheral vascular disease
• Congenital heart disease
• Dementia
• Parkinson’s disease
• Epilepsy
• Rare neurological conditions
• Cerebral palsy
• Severe mental illness (bipolar disorder, schizophrenia, or 
severe depression)
• Osteoporotic fracture
• Rheumatoid arthritis or systemic lupus erythematosus
• Cirrhosis of the liver
*Patients with stage 5 chronic kidney disease were assigned the coefficient for stage 5 
disease without transplant nor dialysis. †For the validation of the QCovid risk model, 
all patients with diabetes were assigned the coefficient type 2 diabetes.
Overall Period 1 (Jan 24, to 
April 30, 2020)
Period 2 (May 1, to 
July 31, 2020)
Overall 34 897 648 26 985 13 177
Sex
Female 18 297 773 (52·43%) 11 651 (43·18%) 6560 (49·78%)
Male 16 599 875 (47·57%) 15 334 (56·82%) 6617 (50·22%)
Age, years 51·09 (18·76) 79·98 (11·63) 82·13 (10·79)
Age group, years
19–29 5 601 475 (16·05%) 44 (0·16%) 13 (0·10%)
30–39 5 268 030 (15·10%) 116 (0·43%) 30 (0·23%)
40–49 5 625 225 (16·12%) 364 (1·35%) 125 (0·95%)
50–59 6 435 204 (18·44%) 1196 (4·43%) 400 (3·04%)
60–69 5 185 917 (14·86%) 2727 (10·11%) 962 (7·30%)
70–79 4 225 729 (12·11%) 6280 (23·27%) 2695 (20·45%)
80–89 2 093 545 (6·00%) 10 841 (40·17%) 5580 (42·35%)
≥90 462 523 (1·33%) 5417 (20·07%) 3372 (25·59%)
Geographical region
East Midlands 3 137 521 (8·99%) 1979 (7·33%) 1372 (10·41%)
East of England 3 987 067 (11·43%) 2549 (9·45%) 1456 (11·05%)
London 4 662 731 (13·36%) 5403 (20·02%) 956 (7·26%)
North east 1 755 316 (5·03%) 1429 (5·30%) 931 (7·07%)
North west 4 643 947 (13·31%) 4289 (15·89%) 2411 (18·30%)
South east 5 818 470 (16·67%) 4005 (14·84%) 2118 (16·07%)
South west 3 674 549 (10·53%) 1657 (6·14%) 745 (5·65%)
West Midlands 3 643 447 (10·44%) 3284 (12·17%) 1497 (11·36%)
Yorkshire and the Humber 3 574 600 (10·24%) 2390 (8·86%) 1691 (12·83%)
Ethnicity
Bangladeshi 258 053 (0·74%) 179 (0·66%) 29 (0·22%)
Black African 520 547 (1·49%) 398 (1·47%) 62 (0·47%)
Black Caribbean 374 982 (1·07%) 732 (2·71%) 124 (0·94%)
Chinese 185 966 (0·53%) 107 (0·40%) 27 (0·20%)
Indian 931 247 (2·67%) 800 (2·96%) 216 (1·64%)
Mixed 551 567 (1·58%) 184 (0·68%) 67 (0·51%)
Other 835 506 (2·39%) 590 (2·19%) 130 (0·99%)
Pakistani 679 062 (1·95%) 426 (1·58%) 123 (0·93%)
White British 28 845 085 (82·66%) 22 462 (83·24%) 12 018 (91·20%)
White other 1 715 633 (4·92%) 1107 (4·10%) 381 (2·89%)
Townsend deprivation quintile
1 (most affluent) 7 491 652 (21·47%) 4993 (18·50%) 2842 (21·57%)
2 7 738 292 (22·17%) 5326 (19·74%) 2967 (22·52%)
3 6 834 804 (19·58%) 5111 (18·94%) 2647 (20·09%)
4 6 467 204 (18·53%) 5365 (19·88%) 2472 (18·76%)
5 (most deprived) 6 366 096 (18·24%) 6190 (22·94%) 2249 (17·07%)
Accommodation
Neither homeless nor care home 34 667 007 (99·34%) 19 995 (74·10%) 9039 (68·60%)
Care home or nursing home 230 641 (0·66%) 6990 (25·90%) 4138 (31·40%)
Body-mass index, kg/m²
<18·5 393 928 (1·13%) 983 (3·64%) 614 (4·66%)
18·5 to <25 6 658 276 (19·08%) 5776 (21·40%) 2965 (22·50%)
25 to <30 6 661 721 (19·09%) 5552 (20·57%) 2385 (18·10%)
≥30 5 661 007 (16·22%) 5540 (20·53%) 2066 (15·68%)
Not recorded 15 522 716 (44·48%) 9134 (33·85%) 5147 (39·06%)
(Table 1 continues on  next page)
Articles
4 www.thelancet.com/digital-health   Published online May 25, 2021   https://doi.org/10.1016/S2589-7500(21)00080-7
For comorbidities, we used data from Jan 1, 2015, to 
Dec 31, 2019. For body-mass index (BMI), we used the 
latest recorded value up to December 31, 2019.
The primary care records used in the ONS Public Health 
Linked Data Asset were based on an existing GPES 
dataset, which included many but not all of the relevant 
clinical codes used to develop the QCovid algorithm. 
Nonetheless, we derived data on most of the pre-existing 
conditions. However, we could not identify patients who 
had a solid organ or bone marrow transplant in the past 
6 months, those on kidney dialysis or who had received a 
kidney transplant, or those with sickle cell disease or 
severe combined immunodeficiency syndrome. Similarly, 
we could not distinguish between patients with type 1 or 
type 2 diabetes. Variables used to validate the QCovid 
algorithm are listed in the panel.
Model validation 
We fitted an imputation model to replace missing values 
for BMI, using predicted values from linear regression 
models stratified by sex. Predictors included all predictor 
variables in the QCovid algorithm, interacted with age.
We applied the QCovid risk equations (version 1), which 
are reported in the study that developed the algorithm,14 to 
men and women in the validation dataset. For conditions 
that we could not identify, we could not apply the 
coefficients from the QCovid risk equations. All patients 
with diabetes were assigned the coefficient for type 2 
diabetes. Patients with stage 5 chronic kidney disease were 
assigned the coefficient for stage 5 chronic kidney disease 
without transplant nor dialysis.
Using predicted 90-day risk of COVID-19 death, we 
calculated r² values,21 Brier scores, and measures of 
discrimination and calibration22,23 with corresponding 
95% CIs over the two time periods. r² values refer to the 
proportion of variation in survival time explained by the 
model. Brier scores measure predictive accuracy where 
lower values indicate better accuracy.24 The D statistic is a 
discrimination measure that quantifies the separation in 
survival between patients with different levels of predicted 
risks and Harrell’s C statistic is a discrimination metric 
that quantifies the extent to which people with higher risk 
scores have earlier events. Model calibration was assessed 
in the two time periods by comparing mean predicted 
risks with observed risks by 20ths of predicted risk. 
Observed risks were derived in each of the 20 groups using 
non-parametric estimates of the cumulative incidences.
The performance metrics were calculated in the whole 
cohort and in the following pre-specified subgroups: 
5-year age-sex bands, ten ethnic groups, and within each 
quintile of the Townsend index, a measure of deprivation. 
We also estimated the performance metrics on a sample 
restricted to patients registered with practices using the 
TPP system and therefore not used at all to derive the 
algorithm. The code for this analysis is available on 
GitHub. We also derived the metrics for an alternative 
second period (May 1, 2020, to June 30, 2020), which was 
Overall Period 1 (Jan 24, to 
April 30, 2020)
Period 2 (May 1, to 
July 31, 2020)
(Continued from previous page)
Chronic kidney disease
No chronic kidney disease 34 392 544 (98·55%) 24 425 (90·51%) 11 939 (90·60%)
Stage 3 436 595 (1·25%) 1820 (6·74%) 914 (6·94%)
Stage 4 45 638 (0·13%) 452 (1·68%) 205 (1·56%)
Stage 5 22 871 (0·07%) 288 (1·07%) 119 (0·90%)
Learning disability
No learning disability 34 393 288 (98·55%) 25 300 (93·76%) 12 386 (94·00%)
Learning disability 490 357 (1·41%) 1616 (5·99%) *
Down Syndrome 14 003 (0·04%) 69 (0·26%) *
Chemotherapy†
No chemotherapy in past 12 months 34 776 317 (99·65%) 26 472 (98·10%) 12 908 (97·96%)
Chemotherapy group A 38 956 (0·11%) 128 (0·47%) 62 (0·47%)
Chemotherapy group B 76 763 (0·22%) 339 (1·26%) 180 (1·37%)
Chemotherapy group C 5612 (0·02%) 46 (0·17%) 27 (0·20%)
Cancer and immunosuppression
Blood cancer 336 990 (0·97%) 897 (3·32%) 465 (3·53%)
Respiratory cancer 9720 (0·03%) 142 (0·53%) 66 (0·50%)
Radiotherapy in past 6 months 56 252 (0·16%) 174 (0·64%) 100 (0·76%)
Solid organ transplant 3488 (0·01%) 26 (0·10%) *
Prescribed immunosuppressant 
medication by GP
7237 (0·02%) 20 (0·07%) *
Prescribed leukotriene or LABA 2 362 855 (6·77%) 4956 (18·37%) 2319 (17·60%)
Prescribed regular prednisolone 404 467 (1·16%) 2124 (7·87%) 1028 (7·80%)
Other comorbidities
Diabetes‡ 3 087 792 (8·85%) 8700 (32·24%) 3650 (27·70%)
COPD 1 053 783 (3·02%) 3814 (14·13%) 1809 (13·73%)
Asthma 4 382 954 (12·56%) 3344 (12·39%) 1504 (11·41%)
Rare pulmonary diseases 373 807 (1·07%) 1707 (6·33%) 734 (5·57%)
Pulmonary hypertension or 
pulmonary fibrosis
127 760 (0·37%) 1158 (4·29%) 502 (3·81%)
Coronary heart disease 1 549 243 (4·44%) 5946 (22·03%) 2861 (21·71%)
Stroke 902 277 (2·59%) 5086 (18·85%) 2685 (20·38%)
Atrial fibrillation 1 096 209 (3·14%) 5237 (19·41%) 2894 (21·96%)
Congestive cardiac failure 545 617 (1·56%) 3739 (13·86%) 1830 (13·89%)
Venous thromboembolism 8878 (0·03%) 35 (0·13%) *
Peripheral vascular disease 303 118 (0·87%) 1588 (5·88%) 771 (5·85%)
Congenital heart disease 359 (<0·01%) * 0
Dementia 414 540 (1·19%) 8293 (30·73%) 4699 (35·66%)
Parkinson’s disease 113 647 (0·33%) 1021 (3·78%) 573 (4·35%)
Epilepsy 405 047 (1·16%) 797 (2·95%) 387 (2·94%)
Rare neurological conditions 27 583 (0·08%) 149 (0·55%) 48 (0·36%)
Cerebral palsy 4350 (0·01%) 31 (0·11%) *
Severe mental illness 6 574 526 (18·84%) 5341 (19·79%) 2541 (19·28%)
Osteoporotic fracture 29 153 (0·08%) 194 (0·72%) 92 (0·70%)
Rheumatoid arthritis or SLE 315 431 (0·90%) 696 (2·58%) 369 (2·80%)
Cirrhosis of the liver 81 753 (0·23%) 241 (0·89%) 114 (0·87%)
Data are n (%) or mean (SD). COPD=chronic obstructive pulmonary disease. GP=general practitioner. LABA=long-
acting β2 agonist. SLE=systemic lupus erythematosus. *Represents values that have been suppressed due to small 
numbers (ie, <5). †Groups based on the risk of grade 3 or 4 febrile neutropenia (Common Terminology Criteria for 
Adverse Events version 4) or lymphopenia. ‡Included patients with either type 1 or type 2 diabetes.
Table 1: Demographic and medical characteristics for the validation cohort and those who died with 
COVID-19 in the two time periods 
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the period used in the study that developed the algorithm. 
All analyses were done using R (version 3.5).
The ethics approval for the development and validation 
of QCovid was granted by the East Midlands–Derby 
Research Ethics Committee (18/EM/0400).
Role of the funding source 
This study was funded by a grant from the UK National 
Institute for Health Research following a commission 
by the Chief Medical Officer for England whose office 
contributed to the development of the study question 
and facilitated access to relevant national datasets, 
contributed to interpretation of data, and drafting of the 
report.
Results 
34 897 648 people in England aged 19–100 years met 
our inclusion criteria. Of the 40 136 597 people aged 
19–100 years who were enumerated at the 2011 census 
and were alive on Jan 24, 2020, 2 071 521 (5·2%) people 
were excluded because they could not be linked to the 
2011–13 NHS patient register and therefore did not have 
an NHS number. A further 3 167 428 (7·9%) people could 
not be linked to the GPES data, possibly because they 
migrated out of England and therefore were no longer 
registered with the NHS in England. Our data covered 
80·0% of the population in England aged at least 19 years 
(appendix p 1). Coverage was lowest in London 
(4 662 731 [68·22%] of 6 834 636 people) and highest in 
Yorkshire and the Humber (3 574 600 [83·69%] of 
4 271 381 people; appendix p 1). We estimated that because 
our validation cohort included approximately 80·0% of 
the population in England, approximately 13·9% of 
people in our data were part of the original cohort of 
6 million patients used to develop the QCovid model.
Table 1 shows the baseline characteristics of patients. 
Of all patients, 16 599 875 (47·57%) were men and 
6 052 563 (17·34%) were of ethnic minority background. 
The mean age was 51·1 years, which was slightly higher 
than in the cohort used to derive the QCovid models 
(48·2 years). For most pre-existing conditions, the 
estimated prevalence in the ONS Public Health Linked 
Data Asset is similar to the prevalence in the QResearch 
derivation cohort. However, because the ONS dataset 
is based on primary care data that did not contain a 
list of codes as detailed as in the data used to develop 
the algorithm, the proportion of people taking anti-
leukotriene or long-acting β2 agonists or being prescribed 
oral steroids in the past 6 months was somewhat higher 
in our data than in the cohort used to derive the QCovid 
models.
26 985 (0·08%) patients had a COVID-19-related death 
during the first period (Jan 24 to April 30, 2020). 
13 177 (0·04%) patients had a COVID-19-related death 
during the second period (May 1 to July 28, 2020). Of the 
49 461 COVID-19 deaths that occurred in England over 
the study period, 40 162 (81·2%) were included in our 
data (appendix p 1). Coverage was lowest in London 
(6359 [74·20%] of 8570) and highest in the north west 
(6700 [84·6%] of 7923). In both periods, COVID-19 deaths 
occurred across all regions, with the greatest numbers in 
London in the first period (5403; 20·02% of all deaths) 
and in the north west in the second period (2411; 18·30% 
table 1). Of those who died in the first period, 
15 334 (56·82%) were men, 11 651 (43·18%) were women, 
4523 (16·76%) were from ethnic minority groups, 
22 538 (83·52%) were aged 70 years and older, 
8700 (32·24%) had diabetes, 8293 (30·73%) had 
dementia, and 6990 (25·90%) were identified as living in 
a care home (table 1). Those who had a COVID-19-related 
death in the second period had a similar profile to those 
in the first period but were older (11 647 [88·4%] aged 
70 years and older) and more likely to live in a care home 
(4138 [31·40%]).
Table 2 shows the performance of the risk equations in 
the validation cohort for women and men in the two time 
periods. Overall, the values for the r², D statistics, and 
C statistics were high and similar in women and men in 
both periods (table 2). In the first period, the equation 
explained 76·3% (95% CI 76·0–76·6) of the variation in 
time to COVID-19 death for women and 77·1% 
(76·9–77·4) for men (table 2). All these discrimination 
metrics were higher than in the original QResearch 
cohort used to validate the algorithm. The results were 
similar for the second validation period (table 2). Similar 
results were obtained when restricting the sample to 
14 104 452 patients registered with practices using the 
TPP system (appendix p 1). Metrics obtained when 
restricting the sample to patients with valid BMI 
information were similar but marginally lower than 
Period 1 (Jan 24, to April 30, 2020) Period 2 (May 1, to July 31, 2020)
COVID-19 death in women COVID-19 death in men COVID-19 death in women COVID-19 death in men
r² statistic 0·763 (0·760–0·766) 0·771 (0·769–0·774) 0·754 (0·750–0·757) 0·774 (0·769–0·777)
D statistic  3·671 (3·640–3·702) 3·761 (3·732–3·789) 3·579 (3·542–3·616) 3·782 (3·739–3·826)
Harrell’s C statistic  0·945 (0·943–0·947) 0·935 (0·933–0·937) 0·956 (0·954–0·958) 0·944 (0·942–0·946)
Brier score 0·0018 0·0013 0·0007 0·0008
Data are estimate (95% CI).
Table 2: Performance of the risk models to predict risk of COVID-19 death in the validation cohort 
See Online for appendix
For the code see https://github.
com/ONShmh/QCovid_
validation
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those obtained with the full sample (appendix p 2). 
Metrics for an alternative second period (May 1, to 
June 30, 2020; the period that was used in the study that 
developed the algorithm14) were similar (appendix p 2).
Figure 1 displays Harrell’s C statistic by age group for 
men and women in the first period and second period. 
The Harrell’s C statistics were greater than 0·700 for all 
age bands, indicating that even within each age band the 
model discriminates well (figure 1). The C statistics were 
lower for patients aged 90 years or older than for younger 
patients. The C statistic, r², D statistic, and Brier score 
by age group, deprivation quintile, and ethnic group in 
men and women for both periods are reported in the 
appendix (pp 2–9). Performance was generally similar to 
that in the overall population, except for age where the 
performance was lower within individual age groups 
compared with in the overall population (appendix pp 2–9).
Figure 2 displays the calibration plots for the COVID-19 
mortality equation for men and women and in the first 
period (this analysis was not done for the second period). 
Overall, both sets of equations were well calibrated 
because the predicted and observed risks were similar 
(figure 2). However, as in the original QResearch 
validation cohort, the model underestimated the risk of 
COVID-19 death for those in the top 5% of the predicted 
risk score (figure 2). We obtained similar results 
when restricting the sample to patients registered with 
practices using the TPP system (appendix p 12).
Figure 3 shows the sensitivity values for the mortality 
equation in the first period and second period assessed at 
different thresholds on the basis of the centiles of the 
predicted absolute risk in the validation cohort. Full 
results are reported in the appendix (p 10). Sensitivity 
was higher in women than in men and in the second 
period than in the first period (figure 3). In the first 
period, 65·94% of deaths in men occurred in those in the 
top 5% for predicted absolute risk of death from 
COVID-19 (90-day predicted absolute risks greater 
than 0·29%) and 71·67% of deaths in women occurred in 
the top 5% (predicted absolute risks greater than 0·19%; 
figure 3). In the second period, 71·10% of deaths occurred 
in men in the top 5% for predicted absolute risk of death 
from COVID-19 (predicted absolute risks greater 
than 0·278%) and 77·16% of deaths occurred in women 
in the top 5% (predicted absolute risks greater 
than 0·181%). Sensitivity for the two time periods based 
on relative risks is shown in the appendix (p 12; defined 
as the ratio of the individual’s predicted absolute risk to 
the predicted absolute risk for a person of the same age 
and sex with a White ethnicity, BMI 25 kg/m², and mean 
deprivation score with no other risk factors). In the first 
period, 40·56% of deaths occurred in men and 42·63% in 
women in the top 5% for predicted relative risk of death 
from COVID-19 (figure 2; appendix p 13). In the second 
period, 42·62% of deaths occurred in men and 43·57% in 
women in the top 5% for predicted relative risk of death 
from COVID-19.
Figure 1: Harrell’s C statistic by age group for men and women in the first period and second period
(A) Results for the first period (Jan 24, to April 30, 2020). (B) Results for the second period (May 1, to 
July 28, 2020). Bars represent 95% CIs.
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We report the distribution of predicted risks of 
COVID-19 death by age group and sex in the appendix 
(p 14). The predicted risk increased exponentially with age 
and we found substantial variation in predicted risks 
within age group (appendix p 14).
Discussion 
We validated the QCovid clinical risk prediction model 
for mortality due to COVID-19 using a national external 
linked dataset. We used national linked datasets from the 
2011 census, GP, and death registry data for a population-
representative sample of nearly 35 million adults. The 
risk models had excellent discrimination, were well 
calibrated (predicted and observed risks were similar) 
and had a high sensitivity (two-thirds or more of deaths 
occurred in the people in the top 5% for predicted 
absolute risk of death from COVID-19).
Our study had several important strengths. First, we 
used a unique linked dataset based on the 2011 census 
for nearly 35 million people living in England. Second, 
we used various metrics over two time periods to validate 
the QCovid predictive model. All the performance 
metrics in the two time periods for both men and women 
indicated that the algorithm performs well, despite the 
demographic profile of people who died being slightly 
different in the two periods. The metrics were similar 
to those of the original validation of QCovid in the 
QResearch database.14 The model performance was even 
slightly higher than in the derivation cohort, probably 
because of broader variation in risk factors in this larger 
cohort. Finally, we showed that the model’s performance 
was similar when restricting the sample to patients who 
were registered with practices using a different clinical 
computer system provider (TPP) and therefore not used 
to derive the QCovid model.
This study also has several limitations. First, because of 
data limitations, we could not derive all predictors in the 
same way as in the derivation cohort. Despite these 
inconsistencies, the model had excellent discrimination 
and calibration. Second, we only focused on COVID-19-
related deaths and not hospital admissions because of 
the lack of data. Additionally, early in the pandemic some 
COVID-19-related deaths might not have been recorded 
as such. Third, our sample only contained data from 
approximately 80% of the population aged 19–100 years 
in England. Because the Public Health Data Asset was 
based on the 2011 census, the data excluded approximately 
6% of people who lived in England in 2011 but did not 
take part in the 2011 census. Additionally, the data also 
excluded approximately 5% of 2011 census respondents 
who could not be linked to the 2011–13 NHS patients 
register. Because the dataset was based on individuals 
enumerated at the 2011 census, people who had 
immigrated to England since 2011 were excluded. 
However, recent migrants tend to be younger than the 
native population and therefore at lower risk of COVID-19 
death.25 Our data also excluded people who were not 
registered with the NHS. Another limitation is that an 
estimated 13·9% of patients in our cohort were also part 
of the cohort used for deriving the QCovid model. 
However, we found that the model’s performance was 
similar when using only a subset of patients who were 
registered with practices using TPP and, therefore, were 
not part of the model development cohort, which used 
data from patients registered with EMIS practices. 
Comparing the performance of QCovid to that of other 
risk prediction models in the ONS Public Health Data 
Asset is an important area for further research.
QCovid represents a new approach for population risk 
stratification for adverse outcomes from COVID-19 
and our validation indicates that the risk algorithm 
performs well on external data not used for the 
algorithm’s derivation. A companion study that is 
currently underway is aiming to externally validate 
additional QCovid algorithms that use datasets from 
Wales (SAIL16) and Scotland (EAVE-II17), the results of 
which are to be reported separately. Moreover, despite the 
QCovid algorithm discussed here being specifically 
designed to inform UK health policy and interventions to 
manage COVID-19-related risks, the algorithm also has 
international potential, subject to local validation. The 
QCovid risk model predicts COVID-19 deaths in the 
general population over a fairly short time period, which 
potentially limits the algorithm’s applicability. Predictive 
Figure 2: Predicted and observed risk of COVID-19-related death in the first study period
First study period was Jan 24, to April 30, 2020.
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models that operate over longer time periods are needed. 
QCovid could nonetheless be deployed in several health 
and care applications, either during the current phase of 
the pandemic, or in subsequent waves of infection. 
These applications could include supporting targeted 
recruitment for clinical trials, vaccine prioritisation, and 
discussions between patients and clinicians in relation 
to work and health risks, for example through weight 
reduction given that obesity is the single most important 
modifiable risk factor for serious COVID-19 compli-
cations.7 However, using the model to allow additional 
exposure for people with low predicted risk would 
warrant additional analysis and close monitoring of the 
consequences.
In conclusion, this study presents a robust validation of 
a new prediction model that could be used to support 
population risk stratification in relation to public health 
interventions, for example vaccine use. We anticipate that 
the algorithms will be updated regularly as understanding 
of COVID-19 increases, more data become available, new 
variants emerge, effective treatments for COVID-19 
become available, the vaccination programme rolls out, 
immunity levels change, or as behaviour in the population 
changes (eg, reduced adherence to physical distancing 
rules)  and hence we anticipate that this validation will 
need to be repeated on a regular basis. The existence of a 
common appro priately developed model that is evi dence 
based, consistently implemented, and supported by the 
academic, clinical, and patient communities is important 
for patients, carers, and clinicians. Use of this model will 
then help ensure consistent policy and clear national 
com munication between policy makers, professionals, 
employers, and the public.
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